Diabetes Research

Composition of Gut Microbiome Predicts the Onset of Type 2 Diabetes

University of Turku

New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.

Eli Lilly and Company

Insulin Delivery

Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care

Abbott

Update

KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs

KalVista Pharmaceuticals, Inc.

Drug Pricing

Lilly Expands Insulin Affordability Options

Eli Lilly and Company

Approval

Farxiga Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type-2 Diabetes

AstraZeneca

Drug Pricing

Novo Nordisk Launching Additional US Insulin Affordability Offerings in January 2020

Novo Nordisk

M&A

Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

Vertex

Heathcare

Blue Cross and Blue Shield of Minnesota to Cover Insulin Costs at No Charge Next Year

Blue Cross Blue Shield of Minnesota

Licensing Agreement

Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China

Innovent

FDA Approval

Aptar’s Nasal Unidose Device Approved by US FDA for First Needle-Free Rescue Treatment for Severe Hypoglycemia

Aptar

Diabetes

Forxiga Label Updated in the EU in Type-2 Diabetes

AstraZeneca